loading page

Crosstalk Between Sodium-Glucose Cotransporter Inhibitors and Sodium-Hydrogen Exchanger- 1 and 3 in Cardiometabolic Diseases
  • +9
  • Al-Anood Al-Shamasi,
  • Rozina Elkaffash,
  • Meram Mohamed,
  • Menatallah Rayan,
  • Dhabya Al-Khater ,
  • Alain Gadeau,
  • Rashid Ahmed ,
  • Anwarul Hasan ,
  • Hussein Eldassouki,
  • Huseyin Yalcin,
  • Muhammad Abdul-Ghani,
  • Fatima Mraiche
Al-Anood Al-Shamasi
Qatar University College of Pharmacy
Author Profile
Rozina Elkaffash
Qatar University College of Pharmacy
Author Profile
Meram Mohamed
Qatar University College of Pharmacy
Author Profile
Menatallah Rayan
Qatar University College of Pharmacy
Author Profile
Dhabya Al-Khater
Qatar University College of Pharmacy
Author Profile
Alain Gadeau
University of Bordeaux
Author Profile
Rashid Ahmed
Qatar University College of Engineering
Author Profile
Anwarul Hasan
Qatar University College of Engineering
Author Profile
Hussein Eldassouki
University of Saskatchewan College of Kinesiology
Author Profile
Huseyin Yalcin
Qatar University
Author Profile
Muhammad Abdul-Ghani
The University of Texas Health Science Center at San Antonio
Author Profile
Fatima Mraiche
Qatar University College of Pharmacy

Corresponding Author:[email protected]

Author Profile

Abstract

The hallmark of type 2 diabetes mellitus (T2DM) is abnormal glucose homeostasis due to hyperglycaemia or insulin resistance. Metabolic abnormalities in T2DM lead to cellular dysfunction and the development of diabetic cardiomyopathy and heart failure. New antihyperglycemic agents, such as glucagon-like peptide-1 receptor agonists and the sodium-glucose cotransporter-2 inhibitors (SGLT2i) have shown to attenuate endothelial dysfunction at the cellular level. In addition, they showed cardiovascular safety and cardioprotective effects. How these drugs exert their cardioprotective effects is unknown, although recent studies show that cardiovascular homeostasis occurs through the interplay of the sodium hydrogen exchangers (NHE), specifically NHE1 and NHE3 with SGLT2i. Another theoretical explanation for the SGLT2i cardioprotective effects is through natriuresis by the kidney. This theory highlights the possible involvement of renal NHE transporters in the management of heart failure. This review outlines possible mechanisms predisposing to diabetic cardiomyopathy and discusses the interaction between NHE and SGLT2i in cardiovascular disease.